Vaxart Inc has a consensus price target of $9.25, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from B. Riley Securities, Cantor Fitzgerald, and Cantor Fitzgerald on January 31, 2024, September 7, 2023, and August 7, 2023. With an average price target of $3.33 between B. Riley Securities, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 154.63% upside for Vaxart Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
01/31/2024 | VXRT | Buy Now | Vaxart | $1.31 | 52.78% | B. Riley Securities | Mayank Mamtani | → $2 | Upgrade | Neutral → Buy | Get Alert |
09/07/2023 | VXRT | Buy Now | Vaxart | $1.31 | 205.55% | Cantor Fitzgerald | Charles Duncan | → $4 | Reiterates | Overweight → Overweight | Get Alert |
08/07/2023 | VXRT | Buy Now | Vaxart | $1.31 | 205.55% | Cantor Fitzgerald | Charles Duncan | $6 → $4 | Maintains | Overweight | Get Alert |
12/19/2022 | VXRT | Buy Now | Vaxart | $1.31 | 14.58% | B. Riley Securities | Mayank Mamtani | $6 → $1.5 | Maintains | Neutral | Get Alert |
09/02/2022 | VXRT | Buy Now | Vaxart | $1.31 | 511.11% | Cantor Fitzgerald | Charles Duncan | $11 → $8 | Maintains | Overweight | Get Alert |
05/19/2022 | VXRT | Buy Now | Vaxart | $1.31 | 358.33% | B. Riley Securities | Mayank Mamtani | $7 → $6 | Maintains | Neutral | Get Alert |
11/02/2021 | VXRT | Buy Now | Vaxart | $1.31 | 1045.83% | Cantor Fitzgerald | Charles Duncan | — | Initiates | → Overweight | Get Alert |
06/30/2021 | VXRT | Buy Now | Vaxart | $1.31 | 587.5% | B. Riley Securities | Mayank Mamtani | — | Downgrade | Buy → Neutral | Get Alert |
06/24/2021 | VXRT | Buy Now | Vaxart | $1.31 | 893.05% | Jefferies | Kelechi Chikere | — | Initiates | → Buy | Get Alert |
06/11/2021 | VXRT | Buy Now | Vaxart | $1.31 | 1274.99% | Piper Sandler | Yasmeen Rahimi | — | Initiates | → Overweight | Get Alert |
The latest price target for Vaxart (NASDAQ: VXRT) was reported by B. Riley Securities on January 31, 2024. The analyst firm set a price target for $2.00 expecting VXRT to rise to within 12 months (a possible 52.78% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Vaxart (NASDAQ: VXRT) was provided by B. Riley Securities, and Vaxart upgraded their buy rating.
The last upgrade for Vaxart Inc happened on January 31, 2024 when B. Riley Securities raised their price target to $2. B. Riley Securities previously had a neutral for Vaxart Inc.
The last downgrade for Vaxart Inc happened on June 30, 2021 when B. Riley Securities changed their price target from $13 to $9 for Vaxart Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vaxart, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vaxart was filed on January 31, 2024 so you should expect the next rating to be made available sometime around January 31, 2025.
While ratings are subjective and will change, the latest Vaxart (VXRT) rating was a upgraded with a price target of $0.00 to $2.00. The current price Vaxart (VXRT) is trading at is $1.31, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.